JP2014516702A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014516702A5 JP2014516702A5 JP2014511881A JP2014511881A JP2014516702A5 JP 2014516702 A5 JP2014516702 A5 JP 2014516702A5 JP 2014511881 A JP2014511881 A JP 2014511881A JP 2014511881 A JP2014511881 A JP 2014511881A JP 2014516702 A5 JP2014516702 A5 JP 2014516702A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically active
- active compound
- exendin
- peptide
- here
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 6
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 2
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 108010015174 exendin 3 Proteins 0.000 description 2
- LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 description 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11167534 | 2011-05-25 | ||
| EP11167534.4 | 2011-05-25 | ||
| PCT/EP2012/059752 WO2012160160A1 (en) | 2011-05-25 | 2012-05-24 | Medicament delivery device with dispense interface sensor and method controlling the device |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014516702A JP2014516702A (ja) | 2014-07-17 |
| JP2014516702A5 true JP2014516702A5 (enExample) | 2015-07-02 |
| JP6050331B2 JP6050331B2 (ja) | 2016-12-21 |
Family
ID=44856966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014511881A Expired - Fee Related JP6050331B2 (ja) | 2011-05-25 | 2012-05-24 | 投薬インターフェース・センサを有する薬剤送達デバイスおよびこのデバイスを制御する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9492616B2 (enExample) |
| EP (1) | EP2714147B1 (enExample) |
| JP (1) | JP6050331B2 (enExample) |
| CN (1) | CN103796696B (enExample) |
| DK (1) | DK2714147T3 (enExample) |
| WO (1) | WO2012160160A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8157769B2 (en) | 2009-09-15 | 2012-04-17 | Medimop Medical Projects Ltd. | Cartridge insertion assembly for drug delivery system |
| US9643770B2 (en) | 2012-12-03 | 2017-05-09 | Mylan Inc. | System and method for medicament storage, dispensing, and administration |
| US9692829B2 (en) | 2012-12-03 | 2017-06-27 | Mylan Inc. | Medication delivery system and method |
| US9179260B2 (en) | 2012-12-03 | 2015-11-03 | Mylan Inc. | Medicament information system and method |
| US20140155827A1 (en) | 2012-12-03 | 2014-06-05 | Mylan, Inc. | Medicament information system and method |
| JP6240090B2 (ja) * | 2012-12-13 | 2017-11-29 | パナソニックヘルスケアホールディングス株式会社 | 薬剤注入装置 |
| TR201905783T4 (tr) | 2013-01-16 | 2019-05-21 | Bayer Pharma AG | İlaç enjeksiyon cihazına yönelik kilit. |
| WO2014118111A1 (en) * | 2013-01-29 | 2014-08-07 | Sanofi-Aventis Deutschland Gmbh | Electronic module and drug delivery device |
| US10420922B2 (en) * | 2013-02-01 | 2019-09-24 | The Brigham And Women's Hospital, Inc. | Swellable adhesive needles |
| JP6087423B2 (ja) | 2013-03-08 | 2017-03-01 | パナソニックヘルスケアホールディングス株式会社 | 薬剤注入装置 |
| EP3062841B1 (en) | 2013-10-24 | 2023-06-28 | Trustees of Boston University | Infusion system employing an infusion set for preventing mischanneling of multiple medicaments |
| GB2525149A (en) * | 2014-01-30 | 2015-10-21 | Cellnovo Ltd | Therapeutic product delivery device |
| US10441717B2 (en) | 2014-04-15 | 2019-10-15 | Insulet Corporation | Monitoring a physiological parameter associated with tissue of a host to confirm delivery of medication |
| CN111840696B (zh) * | 2014-06-03 | 2022-12-20 | 安姆根有限公司 | 可控制药物递送系统和使用方法 |
| EP3261692B1 (en) | 2015-02-27 | 2020-08-19 | Novo Nordisk A/S | Accessory device with mounting safety feature |
| CN113181477B (zh) | 2015-06-04 | 2023-07-14 | 麦迪麦珀医疗工程有限公司 | 用于药物释放装置的筒插入 |
| WO2017087888A1 (en) | 2015-11-18 | 2017-05-26 | President And Fellows Of Harvard College | Systems and methods for monitoring, managing, and treating asthma and anaphylaxis |
| ES2924040T3 (es) | 2015-12-30 | 2022-10-04 | Ascendis Pharma As | Autoinyector con sistema de retención de cartucho |
| JP7335072B2 (ja) | 2015-12-30 | 2023-08-29 | アセンディス ファーマ エー／エス | 使用済みカートリッジの検出を備える自動注射器および関連の方法 |
| WO2017114912A1 (en) | 2015-12-30 | 2017-07-06 | Ascendis Pharma A/S | Auto injector with charger safety |
| PL3397321T3 (pl) * | 2015-12-30 | 2023-01-23 | Ascendis Pharma A/S | Automatyczny wstrzykiwacz z regulacją temperatury |
| HUE071013T2 (hu) | 2015-12-30 | 2025-07-28 | Ascendis Pharma As | Autoinjektor adaptálódó légkiürítõ szerkezettel |
| GB201600229D0 (en) * | 2016-01-06 | 2016-02-17 | Vicentra B V | Fluid delivery system |
| EP3419697B1 (en) * | 2016-02-26 | 2024-05-01 | Eli Lilly and Company | Reusable medication delivery device with remaining medication determination capability |
| WO2017207495A1 (en) * | 2016-05-30 | 2017-12-07 | Novo Nordisk A/S | Mounting feature for accessory device |
| WO2017207496A1 (en) | 2016-05-30 | 2017-12-07 | Novo Nordisk A/S | Drug delivery device with zero position adjustment feature |
| US11103652B2 (en) | 2016-06-02 | 2021-08-31 | West Pharma. Services IL, Ltd. | Three position needle retraction |
| US11730892B2 (en) | 2016-08-01 | 2023-08-22 | West Pharma. Services IL, Ltd. | Partial door closure prevention spring |
| CN115591054A (zh) | 2017-05-23 | 2023-01-13 | 阿森迪斯药物股份有限公司（Dk） | 自动注射器、系统和用于控制自动注射器的方法 |
| EP3630226B1 (en) | 2017-05-30 | 2025-10-22 | West Pharma. Services Il, Ltd. | Modular drive train for wearable injector |
| MY203391A (en) | 2017-06-29 | 2024-06-26 | Ascendis Pharma As | Auto injector with reconstitution handling support |
| JP6840891B2 (ja) * | 2017-08-10 | 2021-03-10 | ウェスト ファーマ サービシーズ イスラエル リミテッド | 注射器の自己テストおよびこれに応じた注射器ドアのロック解除機構 |
| MX2020005066A (es) * | 2017-11-16 | 2020-08-20 | Amgen Inc | Autoinyector con deteccion de detencion y punto final. |
| JP7402799B2 (ja) | 2017-12-22 | 2023-12-21 | ウェスト ファーマ サービシーズ イスラエル リミテッド | サイズの異なるカートリッジを利用可能な注射器 |
| US11241532B2 (en) | 2018-08-29 | 2022-02-08 | Insulet Corporation | Drug delivery system with sensor having optimized communication and infusion site |
| CN110548201B (zh) * | 2019-09-09 | 2025-02-21 | 郝云玲 | 一种注射装置 |
| WO2021046680A1 (zh) * | 2019-09-09 | 2021-03-18 | 郝云玲 | 一种注射装置 |
| US12458751B2 (en) | 2020-10-02 | 2025-11-04 | Insulet Corporation | Fluid delivery device having multiple penetrating elements |
| US12433512B2 (en) | 2020-12-18 | 2025-10-07 | Insulet Corporation | Adhesive pad with a metallic coil for securing an on-body medical device |
| EP4059547B1 (en) * | 2021-03-19 | 2025-10-08 | Ypsomed AG | Contact detection system for an injection device |
| US12496398B2 (en) | 2021-05-28 | 2025-12-16 | Insulet Corporation | Threshold based automatic glucose control response |
| WO2022251642A1 (en) | 2021-05-28 | 2022-12-01 | Insulet Corporation | Spring-based status sensors |
| EP4101482A1 (en) | 2021-06-07 | 2022-12-14 | Insulet Corporation | Exercise safety prediction based on physiological conditions |
| EP4669390A1 (en) | 2023-02-24 | 2025-12-31 | SHL Medical AG | DRUG ADMINISTRATION DEVICE POWER SUPPLY UNIT |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1225023A (zh) * | 1996-07-05 | 1999-08-04 | 诺沃挪第克公司 | 剂量设定装置 |
| CA2258308A1 (en) | 1996-07-05 | 1998-01-15 | Novo Nordisk A/S | Dose setting device |
| US5993412A (en) * | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| US7621893B2 (en) * | 1998-10-29 | 2009-11-24 | Medtronic Minimed, Inc. | Methods and apparatuses for detecting occlusions in an ambulatory infusion pump |
| US7766873B2 (en) * | 1998-10-29 | 2010-08-03 | Medtronic Minimed, Inc. | Method and apparatus for detecting occlusions in an ambulatory infusion pump |
| JP3845857B2 (ja) * | 2001-03-15 | 2006-11-15 | ニプロ株式会社 | 簡易薬液注入器 |
| US7033338B2 (en) * | 2002-02-28 | 2006-04-25 | Smiths Medical Md, Inc. | Cartridge and rod for axially loading medication pump |
| ES2555125T3 (es) | 2004-02-18 | 2015-12-29 | Ares Trading S.A. | Dispositivo manual de inyección controlada electrónicamente para inyectar medicamentos líquidos |
| PL1732627T3 (pl) * | 2004-03-31 | 2010-09-30 | Lilly Co Eli | Urządzenie wstrzykujące z kasetą z igłami do aplikowania cieczy farmaceutycznej |
| KR100763050B1 (ko) * | 2004-03-31 | 2007-10-04 | 일라이 릴리 앤드 캄파니 | 액체 약품을 전달하기 위한 니들 카세트를 갖는 주입 장치 |
| CA2631435C (en) * | 2005-12-20 | 2014-08-12 | Antares Pharma, Inc. | Needle-free injection device |
| US7967785B2 (en) * | 2008-07-14 | 2011-06-28 | Nipro Healthcare Systems, Llc | Insulin reservoir detection via magnetic switching |
| TW201200190A (en) * | 2010-03-26 | 2012-01-01 | Sanofi Aventis Deutschland | Electro-mechanical drug delivery device |
| EP2646077B1 (en) * | 2010-11-29 | 2015-06-24 | Sanofi-Aventis Deutschland GmbH | Dispense interface component for a drug delivery device |
-
2012
- 2012-05-24 JP JP2014511881A patent/JP6050331B2/ja not_active Expired - Fee Related
- 2012-05-24 CN CN201280037234.2A patent/CN103796696B/zh not_active Expired - Fee Related
- 2012-05-24 EP EP12723204.9A patent/EP2714147B1/en active Active
- 2012-05-24 US US14/119,211 patent/US9492616B2/en active Active
- 2012-05-24 DK DK12723204.9T patent/DK2714147T3/en active
- 2012-05-24 WO PCT/EP2012/059752 patent/WO2012160160A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014516700A5 (enExample) | ||
| JP2014519900A5 (enExample) | ||
| JP2014516702A5 (enExample) | ||
| JP2014516701A5 (enExample) | ||
| Kaur et al. | Developments of Polysorbate (Tween) based microemulsions: Preclinical drug delivery, toxicity and antimicrobial applications | |
| JP2014531949A5 (enExample) | ||
| BR112022013150A2 (pt) | Derivado da insulina | |
| Sudhakar et al. | Buccal bioadhesive drug delivery—a promising option for orally less efficient drugs | |
| CN115916772A (zh) | 6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用 | |
| Moscona | Medical management of influenza infection | |
| CY1125006T1 (el) | Λιπαρα οξεα και η χρηση τους σε συνδυασμο με βιομορια | |
| Yang et al. | Engineering a long-acting, potent GLP-1 analog for microstructure-based transdermal delivery | |
| JP2010515677A5 (enExample) | ||
| JP2007517016A5 (enExample) | ||
| EA201692282A1 (ru) | Композиция для лечения сахарного диабета, содержащая инсулин и двойной агонист glp-1/глюкагона | |
| JP2019514979A5 (enExample) | ||
| JP2018531984A5 (enExample) | ||
| JP2013533268A5 (enExample) | ||
| JP2018507914A5 (enExample) | ||
| JP2012520866A5 (enExample) | ||
| JP2011241213A5 (enExample) | ||
| JP2012512907A5 (enExample) | ||
| JP2016539921A5 (enExample) | ||
| JP2017519739A5 (enExample) | ||
| BR112012003283A8 (pt) | sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente. |